Pirtobrutinib: A Novel BTK Inhibitor Offering Hope for Hematologic Cancer Patients Short Description:

　　Developed by US-based Lilly,Pirtobrutinib is an innovative oral non-covalent Bruton’s tyrosine kinase(BTK)inhibitor designed for hematologic malignancies.It is indicated for two adult patient populations:

　　1.Relapsed/Refractory Mantle Cell Lymphoma(MCL):Approved for patients who have progressed after at least two prior lines of systemic therapy,including a BTK inhibitor.Approval was granted under accelerated pathways based on response rates,pending confirmation in confirmatory trials.

　　2.Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL):Targets patients who relapsed or became refractory following treatment with covalent BTK inhibitors,addressing an urgent unmet need.

　　Dosage and Administration:

　　●Recommended Dose:200 mg orally once daily as a whole tablet,with or without food,until disease progression or unacceptable toxicity.

　　●Dose Adjustments:

　　○Severe Renal Impairment(eGFR 15-29 mL/min):Reduce to 100 mg daily if current dose is 200 mg;discontinue if 50 mg.

　　○Concomitant Strong CYP3A Inhibitors:Halve Pirtobrutinib dose(discontinue if 50 mg);resume original dose after 5 half-lives of inhibitor discontinuation.

　　○Concomitant Moderate CYP3A Inducers:Increase to 300 mg daily(from 200 mg)or by 50 mg(from 50/100 mg).

　　Safety Management:

　　●Common Adverse Events(≥30%):Fatigue,neutropenia,thrombocytopenia,anemia,etc.,mostly manageable low-grade events.

　　●Key Monitoring and Actions:

　　○Infection Risk:Monitor for life-threatening infections;consider prophylaxis in high-risk patients.

　　○Bleeding:Weigh risks of antithrombotic agents;withhold drug for major bleeding events.

　　○Cytopenias:Perform regular complete blood counts;adjust dose based on severity.

　　○Hepatotoxicity:Monitor bilirubin and transaminases;withhold or discontinue for liver abnormalities.

　　Special Population Considerations:

　　●Pregnancy/Lactation:Potential fetal risk;contraindicated during lactation.Females of reproductive potential must use effective contraception during treatment and for 1 week post-dose.

　　●Geriatric Population:Over 65%of patients in trials were≥65 years old;safety profiles align with younger cohorts,but monitor for increased≥Grade 3 adverse events.

　　Mechanistic Advantages:

　　As a non-covalent BTK inhibitor,Pirtobrutinib uniquely overcomes resistance due to C481 mutations seen with covalent inhibitors,re-establishing BTK pathway blockade.Clinical trials demonstrated ORRs of 56.7-63%in MCL and significant benefits in CLL/SLL.